MONSEY, New York, Nov.  07, 2024  (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Avid Bioservices (NASDAQ:CDMO) ("Avid") to GHO Capital Partners ("GHO") and Ampersand Capital Partners ("Ampersand") for $12.50 per share in cash. The sale price is below the price target for Avid of $14.00 per share of Wall Street analyst Paul Knight of KeyBanc (source: TipRanks). If you remain an Avid …

Benzinga

New York

United States

CDMO Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Avid Bioservices to GHO Capital Partners and Ampersand Capital Partners - Avid Bioservices (NASDAQ:CDMO)

Ad Fontes Media

Media Bias/Fact Check

CDMO Avid Bioservices is being acquired by the private equity firms GHO Capital Partners and Ampersand Capital Partners. Avid specializes in manufacturing biologic products for companies at all stages of development.  The post Private Equity Is Picking Up Biologics CDMO Avid Bioservices in $1.1B Acquisition appeared first on MedCity News.

MedCity News

Private Equity Is Picking Up Biologics CDMO Avid Bioservices in $1.1B Acquisition

Introduction In a significant move that could reshape the landscape of biologics contract development and manufacturing, Avid Bioservices, Inc. (NASDAQ: CDMO) has agreed to be acquired by GHO Capital Partners and Ampersand Capital Partners for approximately $1.1 billion. This all-cash transaction marks a pivotal moment for the Tustin, California-based company, known for its dedication to enhancing patient lives through high-quality services tail…

csimarket.com

#Avid Bioservices Set for Transformation with $1.1 Billion Buyout by GHO Capital and Ampersand

Avid Bioservices, a CDMO specializing in biologic drugs, is going private in a $1.1 billion M&A deal with private equity firms GHO Capital Partners and Ampersand Capital Partners. The deal values Avid at $12.50 per share, a premium to its stock price. Avid was formerly a subsidiary of Peregrine Pharmaceuticals, focusing on CDMO work since 2018. For fiscal 2024, Avid reported a revenue decline to $139.9 million, with top three customers contribut…

Dataemia

After a year of customer pullbacks, biologics CDMO Avid Bioservices will be taken private by GHO Capital Partners and Ampersand Capital Partners in a deal worth $1.1 billion.
“In evaluating this transaction, our Board considered ...

Endpoints News

Avid Bioservices to be sold to private equity firms for $1.1B

Nasdaq-listed CDMO Avid Bioservices has agreed a $1.1bn takeover deal with private equity firms GHO and Ampersand

Pharmaphorum

Avid Bioservices to go private in $1.1bn private equity deal

GHO Capital Partners and Ampersand Capital Partners have agreed to buy biologics CDMO Avid Biosciences in a $1.1bn deal. The post Deal Roundup: GHO, Ampersand seal $1.1bn Avid Biosciences deal, Mutares makes 15th acquisition of 2024 appeared first on AltAssets Private Equity News.

altassets.net

Deal Roundup: GHO, Ampersand seal $1.1bn Avid Biosciences deal, Mutares makes 15th acquisition of 2024

The merger agreement is valued at approximately $1.1 billion.

pharmtech.com

Avid Bioservices Acquired by GHO Capital Partners and Ampersand Capital Partners

GHO Capital Partners and Ampersand Capital Partners will increase their presence in the biomanufacturing space through the planned acquisition of Avid.

CDMO Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Avid Bioservices to GHO Capital Partners and Ampersand Capital Partners - Avid Bioservices (NASDAQ:CDMO)

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics